+

WO1998012304A1 - Systeme de mise en culture de cellules souches hematopoietiques - Google Patents

Systeme de mise en culture de cellules souches hematopoietiques Download PDF

Info

Publication number
WO1998012304A1
WO1998012304A1 PCT/GB1997/002549 GB9702549W WO9812304A1 WO 1998012304 A1 WO1998012304 A1 WO 1998012304A1 GB 9702549 W GB9702549 W GB 9702549W WO 9812304 A1 WO9812304 A1 WO 9812304A1
Authority
WO
WIPO (PCT)
Prior art keywords
hscs
cells
agm
culture
mammal
Prior art date
Application number
PCT/GB1997/002549
Other languages
English (en)
Inventor
Elaine A. Dzierzak
Alexander Medvinsky
Maria-José SANCHEZ
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9619597.9A external-priority patent/GB9619597D0/en
Application filed by Medical Research Council filed Critical Medical Research Council
Priority to AU43111/97A priority Critical patent/AU4311197A/en
Publication of WO1998012304A1 publication Critical patent/WO1998012304A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0648—Splenocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Definitions

  • the invention relates in general to providing a culture of hematopoietic stem cells (HSCs) .
  • HSCs hematopoietic stem cells
  • Hematopoiesis is the process of generating mature blood cells.
  • the adult hematopoietic system of mammals is a dynamic hierarchy of cells with the HSC at its foundation, in that the HSC gives rise to all other cell types of the hematopoietic system.
  • HSCs are rare and generally comprise less than approximately 0.01% of any hematopoietic cell culture.
  • HSCs The source of hematopoietic cells, namely HSCs, and the processes involved in the differentiation of the various hematopoietic cell types from the HSCs, are of considerable interest as they may provide useful tools for therapy, such as bone marrow transplants, gene therapy and for the production of blood related proteins.
  • Dexter and LTC-IC culture systems are able to maintain HSCs; however, cultures of bone marrow or fetal liver cells do not increase HSC numbers in vitro .
  • Hematopoietic cell cultures are difficult to maintain and require complicated media.
  • Hematopoietic events have been determined to begin in the yolk sac (YS) at day 7.5 in gestation (Russell and Bernstein, 1966, "Blood and blood formation” in Biology of the Laboratory Mouse. Second Edition. E.L. Green, ed. , McGraw-Hill, New York, pp. 351-372) and then shift to the fetal liver and later to the spleen and bone marrow (Moore and Metcalf, 1970, Br. J. Haematol.. 18: 279-296; Johnson and Moore, 1975, Nature. 258: 726-728). It was generally accepted that this picture reflected the consecutive migration of HSCs from the YS to the definitive hematopoietic territories.
  • definitive HSC activity has been found in the AGM region at late day 10 p.c, at a time slightly earlier than in the YS and fetal liver (M ⁇ ller et al., 1994, supra). While these results indicate that the intraembryonic AGM region is the most potent pre-liver site of definitive hematopoietic activity, the direct measurement of CFU-S and HSCs within different parts of the embryo as a means of identifying the primary source of definitive hematopoietic activity is not adequate due to the early establishment of the vasculature between the yolk sac and the embryo body, and the active interchange of cells via the circulation and possible interstitial migration as was suggested in amphibian embryos (Turpen and Knudsen, 1982, Dev. Biol. , 89: 138-151).
  • HSCs hematopoietic stem cells
  • the invention is based on the development of an in vitro culture system, and on the discovery that HSC activity is initiated autonomously in the mammalian AGM prior to the appearance of stem cells in the yolk sac and prior to their appearance in the liver.
  • the invention thus provides hematopoietic stem cells and their progenitor cells (i.e., generated in the AGM region) which are less mature than previously-identified stem cells, and which appear to be the founder cells for the differentiated adult blood system and which colonize the other hematopoietic tissues.
  • HSC is herein defined as a pluripotent precursor cell which gives rise to substantially all hematopoietic cell types and has the ability to repopulate the hematopoietic system of a lethally-irradiated mammalian recipient in the long term (that is, longer than 4 months, preferably longer than 8 months and most preferably during the lifetime of the recipient) ; such a cell recipient may be an adult mammal or, alternatively, may be a neonatal mammal.
  • HSCs HSCs
  • Cell types to which HSCs give rise include, but are not limited to, erythrocytes, granulocytes, B- and T-cells, macrophages, megakaryocytes, eosinophils, mast cells, dendritic cells, neutrophils, basophils and N-K cells.
  • Totipotent precursor cells give rise to all such cell types in the sense that they reconstitute the hematopoietic system.
  • cells are defined as including dissociated cells, intact tissue or tissue fragments.
  • tissue refers to intact tissue or tissue fragments, such that the cells are sufficiently aggregated (associated) so as to form a cohesive mass.
  • mammal is defined as any member of the Class Mammalia.
  • the invention thus recognizes the importance of the mammalian AGM region for generation of- and increase in
  • the invention therefore provides a microenvironment for the generation, induction and/or expansion of clinically-useful HSCs.
  • generation is defined to mean the conversion of pre-HSCs to HSCs.
  • pre-HSC is defined to mean a cell that can be induced to give rise to HSCs.
  • induction is defined to mean initiation of division of a quiescent, undifferentiated cell and/or of its development to a more differentiated state.
  • AGM is defined as a pre-liver intraembryonic site of potent definitive hematopoietic activity which is an axial, mesodermally derived region of the mammalian embryo, containing the dorsal aorta, genital ridge/gonads and pro/mesonephros (AGM) and surrounding mesenchymal tissue.
  • the invention also is based on the discovery that the HSC activity generated in the AGM region on culture is at least 15-fold more abundant than in uncultured tissue.
  • HSC activity generated in the AGM region on culture may be any HSC activity generated in the AGM region on culture.
  • HSCs also enable HSC-expansion/induction factors to be identified and cloned using standard techniques such as the phage antibody display system, the RT-PCR differential display method and representational display analysis (RDA) and also enables the identification of cellular components of the AGM to provide a microenvironment which supports HSC generation, expansion and/or induction.
  • RDA representational display analysis
  • the present invention provides an in vitro culture system for the generation or expansion of inducible and/or expandable mammalian hematopoietic stem cells (HSCs) , comprising cells of the AGM of an embryonic mammal and nutrients sufficient to support the generation and/or expansion of mammalian HSCs, and containment therefor.
  • HSCs mammalian hematopoietic stem cells
  • Particularly preferred mammals include mice and humans. It is generally recognized in the art that the human hematopoietic system is substantially analogous with the mouse hematopoietic system, and therefore the present invention is directly applicable to human HSCs.
  • the cells of the culture system comprise tissue. It is additionally preferred that the cells reside on a solid support.
  • a "solid support” refers to any support used for culturing cells such as filters and beads, provided the support is permeable.
  • the culture may contain a variety of hematopoietic cell types including colony-forming-unit spleen cells (CFU-S) , which also may be expanded in the culture.
  • CFU-S colony-forming-unit spleen cells
  • a "CFU-S” is herein defined as a multipotent progenitor cell which gives rise to colonies containing erythroid and myeloid cells. It is preferred that the in vitro culture system comprises CFU-S cells.
  • expandable is used to indicate that the number of HSCs introduced into or originating in the culture can be increased in the culture by at least 10-fold and preferably, at least 15-fold.
  • An increase in the number of HSCs is determined by measuring an increase in HSC activity by testing for in vivo long-term reconstitution of the hematopoietic lineage of a lethally irradiated mammalian recipient.
  • inducible is used to indicate that HSCs, pre-HSCs or stromal cells can be stimulated to produce particular proteins (e.g. growth factors or receptors) and/or form particular hematopoietic cell types. Inducible also may refer to stimulation of cells of the AGM to produce particular proteins.
  • proteins e.g. growth factors or receptors
  • the term "cells of the AGM” is defined to refer to any sub-population of AGM cells which can provide a supportive microenvironment for HSC generation, expansion or induction.
  • exogenous cells refers to cells taken from a source that is outside of the place to which they are returned; for example, exogenous may refer to cells taken from a first mammal or tissue or culture thereof and placed into a second mammal or tissue or culture thereof, or may refer to cross-species cell transplants.
  • endogenous refers to cells that have arisen in- and continuously occupied the tissue in which they are found without ever having undergone removal from- and replacement to that tissue.
  • the phrase "enriched culture” refers to an increased number of HSCs relative to the other cells present in the culture when compared to a corresponding non-cultured AGM from which the HSCs and/or pre-HSCs were derived.
  • the enriched culture has an increased number of HSCs (e.g. at least 15-fold) relative to other cells present in the culture when compared to the in vitro culture of inducible and/or expandable HSCs of the present invention.
  • the AGM is from a first mammal and the HSCs and/or pre-HSCs are from a second mammal.
  • first and second mammals are a single individual of a single species; it is further contemplated that the first and second mammals are different individuals of a single species and the AGM of the first mammal substantially lacks endogenous HSCs and pre-HSCs prior to the introduction of HSCs and/or pre-HSCs from the second mammal in culture; it is also contemplated that the first and second mammals are different individuals of two different species and the AGM of the first mammal substantially lacks endogenous HSCs and/or pre-HSCs prior to the introduction of HSCs and/or pre-HSCs from the second mammal in culture.
  • the first mammal is a non-human mammal
  • the second mammal is a human
  • the AGM of the first mammal substantially lacks endogenous HSCs and/or pre- HSCs prior to the introduction of human HSCs and/or pre- HSCs in culture.
  • the first mammal is immune-deficient.
  • HSCs and/or pre-HSCs of the second mammal are transfected with a gene of interest.
  • the HSC will give rise to all the lineages of hematopoietic cells each containing a copy of the introduced gene.
  • Particularly useful genes include human 3-globin for thalassemias, adenosine deaminase (ADA) , glucocerebrosidase for Gaucher ' s disease, Bruton's trypsin kinase for Crigler najjar syndrome, antiviral constructs, ribozymes and gene repair enzymes.
  • the invention also encompasses an in vitro culture method, comprising culturing cells from the AGM of a mammalian embryo in vitro under conditions which permit generation and/or expansion of HSCs.
  • the cells are cultured on a solid support. It is also preferred that the cells comprise tissue.
  • the method further comprises before the culturing step, the step of substantially purging the cells of the AGM of endogenous HSCs and pre-HSCs, contacting the purged cells with exogenous HSCs so as to form a mixture of cells, and culturing the mixture of cells.
  • the culturing step permits aggregation of the cells to form tissue. It is additionally preferred that the method further comprises the step after culturing of dissociating the cells of the tissue.
  • the method further comprises the step of sorting HSCs from the dissociated cells, although it is possible to inject the entire dissociated cell population into a recipient mammal without such sorting.
  • tissue is cultured at the air/medium interface.
  • air/medium interface is defined as referring to the boundary between the cell culture growth medium and an ambient gas which contacts that medium one or more of its boundaries. This term is used herein interchangeably with “air/liquid interface”. Such an interface may be found on or within 5-10 mm of the upper surface of a pool of culture medium in a container, such as a petri dish or tissue-culture flask.
  • the air/medium interface may occur at a boundary of a solid support on which cells of the present invention are grown, wherein such a support is saturated or perfused with culture medium and one or more surfaces of the support are in contact with an ambient gas.
  • An ambient gas may be atomospheric air.
  • tissue may be either a homogeneous- or a heterogeneous population of atoms or molecules which are found in the gaseous phase and which are represented in a concentration and proportion relative to one another that will support the survival and proliferation of mammalian cells.
  • tissue is cultured at 37°C, under 5% C0 2 , in myeloid long-term culture medium supplemented with hydrocortisone succinate to a concentration of approximately 10 "5 to 10 "6 M.
  • a highly preferred concentration of hydrocortisone succinate is 10 " 5 M.
  • the AGM is taken from a mammal during the stage at which hematopoietic stem cells are maximally prol i ferative in that tissue.
  • this stage is between day 10 and 13 p.c, and more preferably 10 days p.c. or at a comparable stage in another mammal.
  • a preferred equivalent stage is the fifth week of gestation. Appropriate stages of AGM development in other mammalian species may be determined by the methods described herein below.
  • the AGM comprises the anterior section of the AGM.
  • the "anterior section” of the AGM is defined as containing the pronephros, part of the mesonephros, the dorsal aorta, genital ridge/gonads and surrounding mesenchymal tissue.
  • the "posterior section” of the AGM is defined as containing part of the mesonephros, the dorsal aorta, the genital ridge/gonads and surrounding mesenchymal tissue.
  • Another aspect of the present invention is a method of treating a mammal having a deficiency of HSCs, comprising the steps of culturing cells of the AGM of an embryonic mammal in vitro under conditions which permit generation and/or expansion of HSCs to produce HSCs, and administering the HSCs so generated or expanded to a mammal in need thereof.
  • HSC deficiency suitable for treatment include, but are not limited to, leukaemia, sickle cell anaemia, thalassae ias, immune deficiencies, depletion of blood cells through accidental radiation poisoning or as a result of radical medical intervention (such as radiation therapy or chemotherapy for leukemia or other cancers) , lysosomal storage diseases and viral diseases and infections.
  • the cells of the AGM which are cultured comprise tissue.
  • the present invention additionally encompasses a method for identifying receptors on the surface of HSCs, comprising generating and/or expanding HSCs using either the culture system or the culture method described above, and making a comparison of the receptors present thereon with those on cells of the hematopoietic system other than HSCs.
  • the comparison is made using the phage antibody display assay.
  • Another aspect of the present invention is a method for identifying factors produced by HSCs, comprising generating and/or expanding HSCs using either the culture system or the culture method described above, and making a comparison of the factors produced thereby with those produced by cells of the hematopoietic system other than HSCs.
  • comparison is performed using RT- PCR differential display assay of representational display analysis (RDA) .
  • RDA representational display analysis
  • Figure 1 is a schematic representation of the culture system and the assay of cells generated by this system for HSC and CFU-S activities in recipient mice.
  • Figure 2 shows the results of an analysis of CFU-S activity in cultured embryonic tissues.
  • Figure 3 shows a histogram analysis of CFU-S generation potential in cultures and directly transplanted uncultured day 10 p.c. and day 11 p.c. embryonic tissues (for design of the experiment see Figure 1) .
  • Figure 4 shows peripheral blood and multilineage PCR analysis of transplant recipients receiving day 10 p.c. cultured AGM region.
  • Figure 5 shows PCR analysis of recipient peripheral blood for donor cell engraft ent by cultured day 11 p.c. embryonic tissues.
  • Figure 6 shows PCR analysis of peripheral blood DNA from transplant recipients receiving cultured day 10 p.c. anterior or posterior AGM region.
  • Figures 7A to 7D show the results of a cell sorting experiment.
  • Figure 8 shows c-kit expression analysis in AGM and liver cell suspensions from day 10, 11 and 12 p.c embryos.
  • Figure 9 shows cell sorting analysis of cells from the AGM and from the liver
  • Figure 10 shows cytospin preparations of AGM c-kit* sorted cells (top panel) and preparations of liver c-kit * sorted cells (lower panel) .
  • Figure 11 shows the results of a transplantation experiment performed with Mac-1 + and Mac-1 * sorting criteria.
  • Figure 12 shows a Southern blot derived from genomic DNA of mouse peripheral blood prepared from recipients of short- term chimeric AGM/HSC cultures one month after transplant.
  • Figure 13 shows a Southern blot derived from genomic DNA of mouse peripheral blood prepared from recipients of long- term AGM/HSC cultures one month or three months after transplant. DESCRIPTION
  • the invention is based on the discovery that hematopoietic stem cell activity is initiated autonomously in the AGM at day 10 of gestation in the mouse embryo, and thus recognizes the importance of the AGM region at day 10 for generation of HSCs.
  • An culture system has been developed in vitro which provides a microenvironment for induction and expansion of HSCs.
  • the invention provides a culture of HSCs which are at least 15-fold more abundant than in uncultured tissue, and even at least 100- to 200-fold more abundant.
  • the yolk sac, AGM region and the liver were individually cultured in isolation of the other tissues to determine which tissue is the generator of HSCs.
  • the AGM was found to initiate autonomously HSC activity at day 10 in gestation. This is one day prior to the appearance of stem cells in the yolk sac and two days prior to the liver, suggesting that the hematopoietic stem cells generated in the AGM region are indeed the founder cells for the definitive adult blood system and that these cells colonize the other hematopoietic tissues.
  • the invention By providing an expanded culture of HSCs, the invention also provides for identification and cloning of HSC expansion/ induction factors, using standard techniques such as the phage antibody display system, the RT-PCR differential display method and representational display analysis (RDA) .
  • RDA representational display analysis
  • Example 1 presents data that establish that tissue of the AGM has the capacity to induce and promote the expansion of HCSs in culture.
  • Example 2 describes the characterization of HSC cell surface markers which can be used to identify and enrich in a population cells that are of use according to the methods of the invention.
  • Example 3 presents a method by which growth factors and signalling molecules that mediate hematopoietic cell proliferation and differentiation can be identified.
  • Example 4 describes a chimeric culture in which donor cells comprising HSCs are co-cultured with recipient AGM tissue that has been purged of hematopoietic precursors.
  • Example 5 describes the transfection of HSCs obtained according to the methods of the invention with a gene of interest prior to transplantation of the cells into a recipient mammal.
  • Example 6 presents methods by which a human hematopoietic stem cell population may be generated and/or expanded in AGM tissue or cells.
  • Example 7 presents long-term culture of HSCs in AGM tissue.
  • Example 8 describes methods by which dissociated or cloned cells of the AGM may be prepared for HSC culture.
  • AGM is defined as a pre-liver intraembryonic site of potent definitive hematopoietic activity which is an axial, mesodermally derived region of the mammalian embryo, containing the dorsal aorta, genital ridge/gonads and pro/mesonephros (AGM) .
  • An culture derived from mouse AGM is described below.
  • temporal staging experiments e.g. by staining variously aged embryos with an antibody directed against an HSC-specific marker, such as CD34. Morphologically, AGM tissue is very similar among mammals, facilitating such an analysis.
  • AGM hematopoietic and non-heraatopoietic tissues from embryos are used for cultures (see below and Figure l) .
  • the AGM region, YS, liver, head/heart, as well as other pooled tissues (body remnants) are dissected from day 9, 10 and 11 p.c. mouse embryos and cultured in L-15 medium supplemented with 5% fetal calf serum.
  • Embryo age is determined starting with day 0 p.c. on the morning of vaginal plug discovery. When necessary, somite pairs are counted to determine more accurately embryo age.
  • mice Following culture, the embryonic tissues are treated with 0.04% collagenase, pipetted into a single cell suspension, counted and transplanted intravenously into irradiated (1000 rads of a 60 Co source) adult female mice. This procedure is as described earlier (M ⁇ ller et al . , 1994, supra) except that no supporting cells are injected. Mice are housed in positive pressure cabinets and receive neomycin (0.16 g/100 ml) with drinking water for the first month following irradiation and transplantation.
  • Tissues are cultured at 37°C, 5% C0 2 in myeloid long-term culture media (Alpha MEM, horse serum 12.5%, fetal bovine serum 12.5%, 2-mercaptoethanol 10 " *M, i-inositol 0.2mM (optional), folic acid 20 ⁇ M (optional) (Stem Cell Technologies Inc , Toronto) supplemented with hydrocortisone succinate (Sigma) to yield a final concentration of 10 "6 M.
  • Alpha MEM horse serum 12.5%
  • 2-mercaptoethanol 10 " *M i-inositol 0.2mM
  • folic acid 20 ⁇ M optionalal
  • hydrocortisone succinate Sigma
  • the tissues are dissociated with 0.04% collagenase, cells counted and transplanted intravenously into irradiated adult recipients as previously described (Medvinsky et al., 1993, supra; Miiller et al., 1994, surpa) for CFU-S and long-term repopulation (HSC) assays.
  • HSC activity assay the sex of the embryos is determined during the culture period by PCR analysis using oligos which amplify a 342 base pair fragment of the YMT 2/B gene on the Y chromosome, and only male embryonic tissues are transplanted.
  • oligonucleotide primer sequences used are: YMT2-1 CTG GAG CTC TAC AGT GAT GA [SEQ ID NO: 1] YMT2-2 CAG TTA CCA ATC AAC ACA TCA C [SEQ ID NO: 2] Staging to determine human AGM
  • yolk sac hematopoiesis begins in the middle of the third week of gestation and decreases from week 5 until week 7 when it disapears. It is thought that yolk sac hematopoietic cells colonize the fetal liver.
  • yolk sac BFU-Es burst forming units-erythroid
  • liver BFU-Es increase
  • Further descriptive analyses suggest early thymus colonization at week 7 (Haynes et al., 1988, J. EXP. Med..
  • Clonogenic myeloid progentiors have been found in the yolk sac and body of 25 to 50 day gestational stage human embryos (Huyhn et al., 1995, Blood. 86: 4474-4485). Erythroid and multipotent progenitors are also present in these tissues, and between 30 and 40 days into gestation, as many non- erythroid progenitors are found in the eviscerated embryo as in the liver. Descriptive immunhistoche ical analyses have localized a cluster of cells adhering to the ventral endothethial wall of the dorsal aorta in 5-week preumbilical human embryos.
  • HSC expansion and differentiation is determined as follows: For CFU-S assay the recipient mice are sacrificed on day 11 post-transplantation, their spleens are removed and fixed in Bouin's solution (see Humason, G.L., 1979, Animal Tissue Techniques. 4th Edition, W.H. Freeman and Company, San Francisco) . Spleen colonies are counted under a dissecting microscope. For the long-term repopulating activity (HSC) assay, the peripheral blood of recipient mice is analysed 2 times; once at 1.5 to 2.5 months and then at 5.5 to 8 months post-transplantation.
  • HSC long-term repopulating activity
  • Blood (100-200 ⁇ l) is collected from the tail vein of the mice and digested with proteinase K, followed by phenol-chloroform extraction and isopropanol precipitation as previously described (M ⁇ ller et al., 1994, supra). Donor male cell contribution is assessed semi-quantitatively by PCR using YMT2/B primers and yogenin gene specific oligos as the DNA normalization control
  • the myogenin specific oligos used are: MYO-1 TTA CGT CCA TCG TGG ACA GC [SEQ ID NO: 3] MYO-2 TGG GCT GGG TGT TAG TCT TA [SEQ ID NO: 4]
  • the reactions for the combination of YMT2/B and myogenin oligos are initial heating at 95°C for 5 minutes, followed by 30 cycles at 94 °C for 10 seconds, 60°C for 30 seconds and 72°C for 35 seconds and a final single cycle at 37°C for 10 minutes.
  • the cycles are performed in any of a number of commercially available thermocyclers, e.g. a Techne PHC-2 thermocycler.
  • the sizes of the amplified products are 342 bp (YMT2/B) and 245 bp (myogenin) .
  • the products are separated on 2.0% agarose gels and transferred to nylon membranes followed by hybridization with 32 P-labeled YMT2/B and myogenin (MYO) specific probes.
  • the percentage of engraftment is determined by quantitation of radioactive fragments on a phosphorimager and plotting on a graph derived from data obtained in the same PCR of serial dilutions of male DNA (M ⁇ ller et al., 1994, supra), i. Multilineage analysis of donor cell contribution To test the contribution of donor HSCs from day 10 p.c. cultured AGM in the different lympho/hematopoietic lineages in long-term transplanted mice, positive animals are sacrificed and analysed. The following tissues and cells are analysed; peripheral blood, bone marrow, thymus, spleen, lymph nodes, B-cells, macrophages and mast cells (M ⁇ ller et al., 1994, supra).
  • B-cells from spleen cell suspensions are enriched in culture by stimulation with 10 mg/ml lipopolysaccharide (Sigma) for 3 days; macrophages are initially enriched as an adherent cell fraction from the peritoneum and spleen, followed by expansion in culture with 10% L929-conditioned medium (source of M-CSF) for 4-10 days; mast cells are cultured for 5 weeks in 10% WEHI-3 conditioned medium.
  • Enrichment of B cells is determined by antibody staining specific for B220 and FACS analysis; in a representative experiment, 97.5% enrichment was observed. Macrophages are stained directly in culture with Mac-1 antibody; 100% of cells are found to be positive for this marker.
  • Mast cells are stained with IgE antibody (Clone SPE-7, Sigma) followed by a secondary PE conjugated goat anti-mouse antibody (Southern Biotechnology Associates, Inc); in a sample experiment, 53-81% of cells were found to be positive by FACS analysis. These antibodies are, therefore, efficacious in binding these several cell types. Ficoll gradient fractionation is performed to remove dead cells from the B cell cultures.
  • Embryos of the desired developmental stage (the day of appearance of the vaginal plug in mated females is designated as day 0) are removed and embryonic tissues (AGM region and liver) dissected as previously described (Miiller et al., 1994, supra). Cell suspensions are obtained by incubation of embryonic tissues at 37 °C for 1 h in 0.04% collagenase (Sigma) in L-15 medium (Flow Lab) supplemented with fetal calf serum (5-10%) followed by gentle mechanical dispersion. Viable cells are counted using trypan blue exclusion.
  • Cells are suspended in L-15 medium with 5% FCS. Incubation with CD16/CD32 Ab is performed for 20 minutes on ice to lower non-specific staining, followed by incubation with specific mAbs for 20- 30 minutes on ice. Cells are washed twice and incubated with labeled streptavidin, such as PE-conjugated streptavidin (e.g. as supplied by Pharmingen) or Red-670 streptavidin (e.g. that supplied by Gibco BRL) when required. Labeled cells are finally washed twice in L-15 medium, resuspended in the same medium containing 0.5 mg/ml propidium iodide (PI, Sigma) and filtered through a nylon mesh screen to remove debris.
  • labeled streptavidin such as PE-conjugated streptavidin (e.g. as supplied by Pharmingen) or Red-670 streptavidin (e.g. that supplied by Gibco BRL) when required. Labeled cells are finally was
  • Antibodies of use according to the invention include, but are not limited to the following: FITC anti-c-kit (3C1) , PE anti-CD2 (RM2-5) , PE anti-CD4 (RM4-5) , PE anti-CD8 (53-6.7), PE anti-Mac-1 (Ml/70), PE anti-CD16/32 (2.462), PE anti-CD44 (IM7) , PE anti-B220 (RA3-GB2), PE anti-Gr-1 (RB6-8C5) , PE anti-Thy 1.2 (53-2.1), PE anti-Sca-1 (E13-161.7), PE anti-Terll9, biotinylated anti-CD34 (RAM34) and biotinylated AA4.1.
  • FITC anti-c-kit 3C1
  • PE anti-CD2 RM2-5)
  • PE anti-CD4 RM4-5
  • PE anti-CD8 53-6.7
  • PE anti-Mac-1 Ml/70
  • PE anti-CD16/32 2.462
  • PE anti-CD44
  • Viable cells are defined by exclusion of Pl-positive and high obtuse scatter or low forward scatter on a dual-laser FACStar Plus or Vantage cell sorter (Becton Dickinson, San Jose, CA) . Analyses are performed on a fluorescent cell sorter. Sorted cells are collected and counted and, when possible, re-analyzed for purity (>90%) . Control cells may be stained with any of a number of labeled primary antibodies; in the experiments described below, biotinylated rat IgG 2a/a was employed, followed by streptavidin-PE, PE- conjugated IgG 2b or FITC-conjugated IgG 2b (also available from Pharmingen) .
  • cell suspensions are prepared from femoral bone marrow or spleen and stained with B220 or Mac-1. iii. Reconstitution analysis.
  • mice For transplantation of sorted embryonic cells, 2 to 3 month old female mice are used as recipients. Mice are irradiated with a split dose of 1000 rads from a 60 Co source as previously published (M ⁇ ller et al., 1994, supra). After irradiation, mice are maintained on antibiotic water containing 0.16% neomycin sulfate (Sigma) for 4 weeks. Cells are injected intravenously (0.5 ml per mouse) in the tail vein of irradiated recipients. Transplanted animals are bled from the tail vein at 1-2 months and 5-8 months post- transplantation to monitor reconstitution. PCR analysis is performed on peripheral blood DNA for the presence of the donor-specific marker gene. In the case of the experiments described below, the LacZ gene was employed; however, any molecular marker not present in recipient cells may be used. An endogenous marker, such as a housekeeping gene against which expression of the donor may be quantified, is also amplified.
  • Genomic DNA is isolated from peripheral blood and tissues of recipient animals as previously described (M ⁇ ller et al., 1994 supra) .
  • DNA samples 200 ng are analyzed by PCR using the following oligonucleotide primers: for myogenin- specific sequences (Myol) TTACGTCCATCGTGGACAGC [SEQ ID NO: 3] and (Myo2) TGGGCTGGGTGTTAGTCTTA [SEQ ID NO: 4]; and for LacZ specific sequences (lacZl) GCGACTTCCAGTTCAACATC [SEQ ID NO: 5] and (lacZ2) GATGAGTTTGGACAAACCAC [SEQ ID NO: 6].
  • DNA is subjected to an initial 5 minute denaturation at 94 °C followed by 30 cycles of denaturation (5 seconds at 94 C C) , annealing (30 seconds at 60°C) and elongation (30 seconds at 72°C).
  • Serial dilutions of blood DNA from a transgenic animal are used as a PCR control to evaluate the levels of donor cell reconstitution in transplanted mice.
  • the sizes of the amplified LacZ and myogenin PCR products are 670 bp and 245 respectively. The products are separated on 1.5-2% agarose gels, transferred to nylon membranes and hybridized with myogenin and Lac-Z probes.
  • genomic DNA is isolated from bone marrow, spleen, lymph nodes, blood and thymus.
  • B cells are either enriched by sorting B220 + cells from bone marrow or spleen or by a spleen cell suspension culture stimulated with 10 mg/ml lipopolysaccharide (Sigma) for 7 days.
  • Macrophages are either enriched for Mac-1 + cells from bone marrow or spleen or as an adherent cell fraction from the peritoneum followed by expansion in culture with 10% L929 conditioned medium for 4-10 days.
  • Preparation of a chimeric organ culture AGM tissues are isolated from Ell mouse embryos, e.g. from (CBAxBlO)Fl mice, and cultured as described above except that the explanted tissues are irradiated with 0, 500, 750 or 1000 rads of gama irradiation.
  • EXAMPLE 1 a Induction and expansion of CFU-S in cultured, isolated embryonic tissues Using an experimental approach whereby isolated embryonic tissues can be cultured separately from other tissues so that cells cannot migrate or circulate between hematopoietic sites, the AGM region, YS and liver were examined for the generation of definitive CFU-S progenitors. As shown in Figure 1, the culture system was established with whole embryonic tissues cultured on semi-permeable filters at the air/medium (or "air/liquid") interface for 2-3 days followed by dispersion into a single cell suspension and injection into lethally irradiated mice. When day 9 p.c. tissues from 13 embryos were individually cultured and cell suspensions injected, no CFU-S were found
  • CBA x C57B1/10 FI embryos were cultured separately for 3 days. Each group of tissues was pooled and transplanted into five irradiated (CBA x C57B1/10) FI adult recipients, one embryo equivalent of tissue per recipient.
  • the resultant spleen colonies from one representative experiment were 3 fold more abundant per cultured AGM region (31.4 CFU-S/tissue) than cultured YS (9.2 CFU-S/tissue) and 15 fold more per cultured AGM than per cultured liver (1.8 CFU-S/tissue).
  • the weights of the spleens of the various recipient groups differ dramatically and correspond directly with the number of CFU-S produced. No colonies were observed in the control non-injected recipients.
  • large numbers of CFU-S are also found in cultured liver (0.2 embryo liver equivalents produced confluent spleen colony growth, data not shown) .
  • CFU-S numbers from cultured tissues were compared to directly transplanted tissues (Medvinsky et al., 1993, supra).
  • the cumulative results from numerous experiments at early and mid-day 10 p.c. (32-33, 34-35 and 36-38 somite pair) and day 11 p.c (42 and 46 somite pair) are presented in Figure 3.
  • mice from male embryos were cultured for 2-3 days and cells injected into lethally irradiated female recipients.
  • recipient peripheral blood DNA was tested for the presence of the donor male marker using myogenin gene specific oligos as the DNA normalization control (M ⁇ ller and Dzierzak, 1993, supra; Medvinsky et al. , 1993, supra).
  • Southern blot analysis was performed after gel electrophoresis and hybridization with 32 P-labeled probes for the YMT2/B and myogenin (MYO) specific fragments. An autoradiogram is shown. Controls for donor cell contribution include dilutions of male DNA into female DNA and are as indicated; 100%, 10% and 1%. The percentage contribution in each of the peripheral blood samples is indicated at the bottom of each lane. Note that only strong YMT2/B signal is observed in mice transplanted with cultured
  • HSCs are also autonomously generated and greatly increased (approximately 15 fold, taking into account the embryo equivalents transplanted) within the isolated day 10 p.c AGM region during culture.
  • the culture conditions do not affect the high level multilineage potency of HSCs arising from cultured day 10 p.c AGM and yield identical results to those previously reported with directly transplanted day 10 p.c. AGM region cells (M ⁇ ller et al., 1994, supra).
  • HSC potential at the day 11 p.c. stage of development was examined by culture of YS, liver, body remnants and AGM region.
  • a limiting dilution experiment revealed high level HSC activity in cultured YS and AGM but not in liver or body remnants ( Figure 5) .
  • recipients receiving day 11 p.c. cultured AGM region, YS, liver and body remnant cells were analysed for donor cell contribution by peripheral blood DNA PCR specific for YMT/2B and myogenin. Either 0.25 embryo equivalents (ee) or 0.08 ee of cultured tissues were injected into female recipients. Controls for donor cell contribution are mixes of male and female DNA and are indicated as 100%, 10%, 1% and 0.1%.
  • Percentage contribution of donor-derived cells was determined by phosporimaging and is indicated for individual recipients at the bottom of each lane. While 0.25 embryo equivalents of YS and AGM resulted in high level (greater than 10%) repopulation, only the AGM region was able to give some repopulation with 3 fold fewer cells (0.08 embryo equivalents) and no repopulation was observed when cultured liver or body remnants (Body R) were transplanted, indicating a difference in the number of HSCs and/or the potency of the HSCs between these tissues. Finally to determine the earliest stage at which HSC activity can be generated, day 9 p.c. embryonic tissues was cultured.
  • the mesodermal region that forms the AGM is composed of the dorsal aorta, the pronephros, mesonephros and the genital ridge.
  • the metanephros the primordium for the adult kidneys
  • the gonads form here (Kaufman, 1992, The atlas of mouse development.. Academic Press, London, UK. pp. 465-468) .
  • the data obtained from amphibian and fish models suggest posterior to anterior migration of hematopoietic cells (Turpen and Knudsen, 1982, supra; Detrich et al. , 1995, Proc. Natl. Acad. Sci. U.S.A.. 92: 10713-10717).
  • the anterior and posterior sections of the AGM region were separated after dissection from day 10 p.c. male embryos ( Figure 6A) .
  • the schematic drawing indicates the tissue comprising this region: pronephros, mesonephros, gonads and dorsal aorta.
  • the anterior AGM region contains the pronephros, parts of the mesonephros, dorsal aorta and genital ridge.
  • the posterior section contains the other parts of the mesonephros, dorsal aorta and genital ridge. These sections were cultured for 2 days and then tested for HSC activity in lethally irradiated female mouse recipients.
  • the level of donor-derived reconstitution was determined by Y chromosome specific PCR analysis of peripheral blood DNA (Figure 6B) . Southern blot analysis of PCR-amplified peripheral blood DNA from recipients receiving cultured AGMa (anterior) , AGMp (posterior) , YS or liver was performed. Controls include mixes of male and female DNA as indicated; 100%, 10% and 1% and percentage contribution of male donor cells in individual female recipients is shown for each lane. In two separate experiments at greater than 4 months post-transplantation, the cultured anterior section repopulated all recipients (five out of five recipients) to a much higher percentage (10-100%) than the cultured posterior section.
  • the embryonic origin of the definitive hematopoietic system in adult mammals was unknown.
  • the YS in which the first differentiated hematopoietic cells can be detected, is the source of the founder hematopoietic stem cells for the fetal liver and subsequently the adult bone marrow (Moore and Metcalf, 1970, supra) .
  • the hematopoietic hierarchy of the YS is limited in its complexity and is incomplete compared to that in the definitive hematopoietic territories (Dzierzak and Medvinsky, 1995, supra) .
  • definitive cells such as CFU-S progenitors and HSCs within the early YS (Sonoda et al., 1983, supra; Perah and Feldman, 1977, supra; Symann et al., 1978, supra; Samoylina et al., 1990, supra; Medvinsky et al., 1993, supra; M ⁇ ller et al., 1994, supra; Harrison et al., 1979, Blood. 54: 1152-1157).
  • CFU-S progenitors can be maintained during the 2-3 day culture of whole, intact AGM, YS and liver from day 10, 11 or 12 p.c. embryos.
  • the cultured AGM region can significantly increase the number of CFU-S progenitors within it during the culture period.
  • CFU-S generated within the isolated, cultured AGM region are unable to emigrate and disseminate throughout the embryo (Medvinsky et al. , 1996, supra). Thus, they accumulate in situ and surpass the numbers that can be observed in uncultured AGM region (Medvinsky et al., 1993, supra).
  • the significant delay of onset and the low numbers of CFU-S detected in the isolated, cultured liver and YS strongly suggest colonization of these tissues by AGM generated CFU-S progenitors.
  • AGM region in culture can expand HSCs to numbers that can consistently provide complete hematopoiesis to the adult (in 24 out of 27 recipients) while cultured YS failed to yield HSC activity until day 11 p.c and at a lower frequency than cultured AGM.
  • the AGM region is the first (and possibly the only) tissue initiating development of HSCs at the pre-liver stage of hematopoiesis. It seems likely that HSCs appearing in the YS and in other tissues of the embryo at day 11 p.c. is the result of dissemination of HSCs from the AGM region.
  • HSC expansion in the liver (1-2 days later) overtakes the AGM region, thus suggesting that colonization of the fetal liver by AGM HSCs is followed by further expansion and maturation steps.
  • the significance of such excessive secondary expansion of HSCs in the fetal liver is not clear, taking into account the oligoclonality of adult hematopoiesis (Jordan et al., 1990, supra; Jordan et al., 1990a, Genes Dev.. 4: 220-232).
  • the unique temporal and spatial properties of the embryonic AGM region should lead to a better understanding of the inducing and/or expansion factors necessary for the initiation of the definitive adult hematopoietic system in mammals.
  • the individual cellular components and molecular mechanisms by which the embryo attains HSC expansion provide useful applications for gene therapy.
  • the invention also is useful for induction of pre- HSCs to HSCs.
  • the in vitro cultures offer an advantageous test system for identifying specific developmental hematopoietic defects in numerous recently reported homologous recombination knock out mice (Pandolfi et al., 1995, Nature Genetics. 11: 40-44; Tsai et al., 1994, Nature. 371: 221-226; Okuda et al., 1996, Cell. 84: 321-330; Scott et al., 1994, Science. 265: 1573-1577).
  • homozygous mutant mice die between day 11-16 p.c. and show a lack of definitive hematopoiesis.
  • Analysis of YS, AGM and liver from mutant day 10-11 p.c. embryos in the culture system described here should indicate whether deficiencies occur in the pre-stem cell, stem cell, progenitor cell or microenvironmental compartments .
  • EXAMPLE 2 Preparation of an enriched in vitro culture of inducible and/or expandable HSCs
  • standard cell separation techniques Such standard techniques are described below as well as HSC markers, in order to determine whether an enriched culture of HSCs is obtained according to the invention.
  • c-kit * (Rl)
  • c-kit lo (R2)
  • c-kit " (R3).
  • the c-kit * populations of both the AGM region and liver appear to contain cells mainly with high forward scatter indicating that they are large in size.
  • Side scatter analysis shows that all populations of AGM cells are highly granular (with the c-kit * population most granular) when compared to liver. Varying numbers of cells from each of the c-kit sorted regions were transferred into unmarked irradiated recipient mice and donor cell engraftment measured at one month and greater than six months post-transplantation.
  • Recipient peripheral blood DNA was analysed by PCR for the presence of the donor LacZ transgene.
  • blood DNA samples from animals receiving c- kit to and c-kit ' cells from AGM or liver were negative ( ⁇ 1%) for donor Lac-Z signal. Only when c-kit * cells were transplanted did recipients exhibit high level donor cell repopulation.
  • the cumulative results from several experiments demonstrate that high-level reconstituting activity resides only in the c-kit * population.
  • a mean of 6.6 ⁇ 4.5 x 10 3 c-kit * cells from AGM yielded 12 out of 20 reconstituted recipients.
  • 10- fold more cells or a mean of 63 ⁇ 32 x 10 3 c-kit * liver cells are needed to get similar reconstitution in 7 out of 13 recipients.
  • Recipients reconstituted with liver c-kit * cells did not show the same stability in repopulation as the AGM recipients.
  • Three out of nine recipients decreased peripheral blood signal from 100% to 10%.
  • c-kit expression was analysed in AGM and liver cell suspensions from day 10, 11 and 12 p.c embryos. As shown in Figure 8, increases in the percentage of c-kit * cells are found at day 11 p.c. in both AGM and liver when compared to day 10 p.c However, at day 12 p.c, the percentages decrease in both tissues but remain higher than at day 10 p.c. To determine whether these changes were reflected in the functional characteristics of these c-kit * populations, reconstitution experiments were performed (Table 3) . Peripheral blood DNA of each of the recipients was examined by PCR for the presence of the donor Lac-Z transgene.
  • liver c-kit * cells at day 11 p.c. When considering the number of embryo equivalents, the reconstitution potential of liver c-kit * cells at day 11 p.c. is similar to the AGM c-kit * cells, although 10 times more liver c-kit * cells are required.
  • the liver c-kit * population appears to contain more abundant HSC activity than the AGM region.
  • no repopulated recipients were observed with day 10 p.c. c-kit * AGM or liver cells.
  • c-kit has been shown to be expressed not only in HSCs but also in committed hematopoietic progenitors cells and non-hematopoietic cells. Most notably, it has been shown to be expressed on primordial germ cells (PGC) located in the genital ridges of the AGM region.
  • PPC primordial germ cells
  • Mac-1 was present in a significant fraction of c-kit * cells in the AGM region (11%) and liver (22%). In both tissues, no significant co- expression with c-kit was observed for the erythrocyte associated antigen TER119 or Thy-1 (although Thy-1 * cells represent 14% of c-kit " AGM cells) .
  • HSC associated antigens Sca-1, AA4.1, CD34 and CD44 were also analysed. Sca-1 * cells represent less than 1% of the c-kit * population in the AGM region and the liver. However, 20% of AGM c-kit * cells and 94% liver c-kit * cells express high levels of CD44.
  • c-kit * population of the AGM is CD44 " .
  • CD34 another HSC associated antigen is expressed on 20% of c-kit * AGM cells and on 37% of c-kit * liver cells.
  • AA4.1 which is found on HSCs as well as pre-B cells is expressed on 18% of c-kit * AGM region cells and 8% of c-kit * liver cells.
  • c-kit As c-kit is also expressed in primordial germ cells, the c-kit * cells of the AGM region and liver were analysed for expression of the enzyme alkaline phosphatase (AP) .
  • AP alkaline phosphatase
  • Figure 9B cytospin preparations of AGM c-kit * sorted cells showed 15% AP * cells (top panel) and 0% AP * cells in the liver c-kit * sorted cells (bottom panel) .
  • 2-3 % AP * cells were detected (data not shown) .
  • CD34 has been previously used to enrich for HSCs in the adult mouse bone marrow. To determine whether CD34 expression may discriminate a c-kit * subpopulation with HSC activity in the day 11 p.c. AGM region and liver, transplantation studies were performed with c-kit and CD34 stained and sorted cells. As shown in Figure 3A, sorting gates were set for c-kit * CD34 * (Rl) and c-kit * CD34 " (R2) subpopulations from the AGM and liver and varying numbers of cells injected into irradiated recipients. Peripheral blood DNA was analysed for the presence of the donor Lac- Z marker in these recipients at 6-10 months post- transplantation.
  • Mac-1 * in c-kit * CD34 * AGM HSCs
  • a distinctive embryonic marker could be found on AGM and early fetal liver HSCs
  • such cells were examined for the expression of Mac-1.
  • Previously it has been shown that in the day 13 p.c liver, all HSCs are Mac- 1 * .
  • triple staining was performed with c-kit, CD34 and Mac-1 specific antibodies on day 11 p.c. AGM region and liver. Whereas most (81%) liver c-kit * CD34 * cells are Mac- 1*, a smaller fraction (60%) of AGM region cells c-kit * CD34 * are Mac-1 * .
  • Transplantation experiments were performed with Mac-1 * and Mac-1 " sorting criteria ( Figure 11) .
  • EXAMPLE 3 Use of the in vitro culture of inducible and/or expandable HSCs in assays for identifying expansion and/or inducing factors, and the cognate receptors.
  • a. Expression cloning of novel hematopoietic stem cell expansion and/or inducing factors and cloning of the cognate receptors.
  • growth factors and cytokines factors signals hematopoietic cell proliferation and differentiation through cell surface receptors. While many hematopoietic factors and cytokines have been found to act on hematopoietic progenitor cells of the adult bone marrow, none have been found to specifically lead to the proliferation of hematopoietic stem cells without differentiation.
  • HSC in vitro culture of the present invention gives a unique opportunity to isolate novel inducing and/or expansion factors for hematopoietic stem ells. It has been found that during a small window of developmental time (days 10 through 13 in mouse gestation) hematopoietic stem cells increase in number in cultured AGM region. Accordingly, it is possible to use the HSC culture of the present invention to clone cell surface and secreted molecules involved in hematopoietic stem cell induction and expansion.
  • phage antibody display libraries to isolate single-chain Fv antibodies specific for cells of interest.
  • Using the phage antibody display system it is possible to isolate antibodies having affinity for HSCs and to use the antibodies to isolate proteins produced by HSCs or receptors on the surface of HSCs or which have an effect on HSC maturation or proliferation.
  • Such a library has been used for isolating antibodies specific for human B cells, T cells and eosinophils from peripheral blood (de Kruif et al., 1995a, J. Mol. Biol.. 248: 97-105; de Kruif et al., 1995b, Proc. Natl. Acad. Sci. U.S.A..
  • AGM region may also be used according to the invention to isolate antibodies specific for AGM region, particularly the anterior portion of the AGM which contains the pro/mesonephros and dorsal aorta.
  • this portion is responsible for the generation of high level hematopoietic stem cell activity.
  • transgenic mice expressing marker genes in hematopoietic stem cells expression has been seen in these sites (the pro/mesonephric tubules and cells surrounding the aorta (unpublished observations) of day 10-13 embryos) .
  • a phage antibody library is tested on frozen sections of anterior AGM tissue.
  • the phage antibody library is pre-absorbed on day of 9 AGM region which does not yet contain hematopoietic stem cells. After specific binding to day 10-13 AGM, individual phage are eluted and tested on day 11-13 liver. However, because hematopoietic stem cells from the AGM region appear to colonize the liver and continue to expand at day 11 and because the liver rudiment is derived from a different germ cell layer than the AGM region, only phage specific for the surface molecules of hematopoietic stem cells should bind. The specific phage is grown in large quantities. Phage antibody is then used in HSC culture experiments.
  • the expansion and/or inducing factors to the cell surface receptors are cloned.
  • An absorption of the phage antibody library on sorted AGM hematopoietic stem cells is first performed.
  • the phage antibodies that remain unbound are incubated with sections of anterior AGM taken from culture.
  • Selected phage antibodies are isolated and grown.
  • Inhibition of hematopoietic stem cell production in HSC cultures by the individual phage antibodies is tested.
  • Those that inhibit stem cell production are then used to isolate the specific inducing/expansion factors. Protein sequencing and gene cloning are performed, and the genes are overexpressed in order to produce large quantities of these proteins for use in the culture experiments.
  • Another type of cloning can be performed using the cultured material.
  • This is an RT-PCR differential display method.
  • This method allows a relatively rapid detection of differentially expressed genes, including transcripts of low abundance (Liang et al., 1992, Science. 257: 967-971; Guimaraes et al., 1995a, Nucleic Acids Res.. 23: 1832- 1833; Guimaraes et al., 1995b, Development. 121: 3335- 3346) .
  • a further enrichment for differentially-expressed transcripts of specific gene families may be obtained through the use of specific oligonucleotide primers for highly conserved domains such as the zinc fingers of transcription factors or tyrosine kinase domain of membrane receptors.
  • Day 9 AGM region RNA are taken and compared to day 11 AGM RNA using the differential display method.
  • the unique clones are then compared to day 11 liver RNA, which should contain some similar clones since hematopoietic stem cells are present and expanding in both tissue at this time.
  • These clones are isolated and the full length cDNA cloned and sequenced. The function of the resulting molecules is tested in the culture as described above and on CD34+ cells from human bone marrow.
  • RDA representational display analysis
  • the culture method facilitates both the cloning of novel genes as well as testing the activity of cloned genes and novel expansion/inducing factors.
  • EXAMPLE 4 Induction of hematopoietic stem cells in chimeric AGM cultures.
  • E10 AGM explants autonomously and exclusively initiate hematopoietic stem cells and increase their number.
  • a chimeric culture system was developed.
  • the recipient tissue is conditioned so as to eliminate developing cells of interest but not the cells of the microenvironment.
  • Exogenous test cells (containing some distinguishing molecular marker) are then introduced into the (unmarked) ablated tissue.
  • the chimeric tissue is cultured and subsequently tested qualitatively and quantitatively for the generation of marked cells of the desired cell type.
  • the chimeric culture protocol for the generation of hematopoietic stem cells is as follows:
  • Ell AGM explants (which are highly active in the initiation of hematopoietic stem cells) were treated with doses of gamma irradiation ranging from 1000 to 0 Rads to eliminate endogenous hematopoietic stem cell activity but not the cells of the microenvironment. These treated (or "purged") Ell explants were injected with exogenous cells isolated from mouse embryonic day 9 (E9) yolk sac or AGM of transgenic (line 72; integration at?-globin locus) embryos. E9 tissues were used, since no hematopoietic stem cell activity can be detected either in E9 yolk sac or AGM cells explants directly transplanted into recipients or in untreated E9 yolk sac or AGM cultures.
  • the chimeric AGM tissues were harvested and digested with collagenase and single cell suspensions (.75 embryo equivalents) were injected into lethally-irradiated adult mouse recipients (CBAxBlO Fl mice; 900 Rads) to test for hematopoietic stem cell activity.
  • the chimeric cultures can induce and expand hematopoietic stem cell activity from exogenous sources thought to contain pre-hematopoietic stem cells.
  • HSC cultures obtained according to the invention are transfected with a gene of interest, and the transfected cells administered to a recipient mammal in need of the transfected gene of interest.
  • Transfection of hematopoietic stem cells are described in Mannion-Henderson et al., 1995, Exp. Hematol.. 23: 1628; Schiffmann et al., 1995, Blood. 86: 1218; Williams, 1990, Bone Marrow Transplant. 5: 141; Boggs, 1990, Int. J. Cell Cloning. 8: 80; Martensson et al., 1987, Eur. J. Immunol.. 17: 1499; Okabe et al., 1992, Eur. J. Immunol.. 22: 37-43; and Banerji et al., 1983, Cell. 33: 729.
  • Administration of transfected cells is described below.
  • HSCs In humans, there are many instances in which it would be advantageous to have a ready supply of HSCs for the purposes of therapeutic administration. These include both naturally-occurring blood cell deficiencies and those induced by radical treatment for other disorders, such as leukemia or other cancers. As previously stated, there is significant homology of the hematopoietic systems among mammals. Animal models, such as the murine culture system of the present invention, provide insight into human developmental hematopoiesis and therapeutic applications. The expansion of a human myeloid leukemic cell in a mouse has been described previously (Lapidot et al., 1994, Nature. 367: 645-648).
  • a colony of mice ( scid/nod) , which are immunologically deficient, tolerate xenografted tissue without subjecting it to immune rejection; therefore, AGM tissue harvested from such mice may be co-cultured with human HSCs that have been pre-enriched by flow-cytometric sorting using antibodies directed at CD34 according to the methods described above and shown in Figure 1.
  • quantitation of HSC generation and/or expansion may be performed by transplanting AGM cells or tissue into a recipient scid/nod mouse and monitoring repopulation of that immune-deficient recipient with human hematopoietic cells, as described in the above Examples; the cells of the AGM to be used for quantitation may be dissociated prior to transplantation, if desired.
  • the scid/nod AGM tissue is digested after culturing with collagenase and the HCSs are again sorted out using an anti-CD34 antibody.
  • cell sorting is highly recommended prior to transplantation into humans in order to avoid an immune response to the mouse AGM cells.
  • the procedures described in Example 5 may be followed prior to transplantation.
  • the transplantation of hematopoietic cells, such as in a bone marrow transplant, is commonly performed in the art by procedures such as those described by Thomas et al.
  • HSCs generated in the in vitro culture system of the present invention are administered via injection, after which point they colonize the hematopoietic system of the recipient host. Success of the graft is measured by monitoring the re-appearance of the numerous adult blood cell types (see Summary, above) by the immunological and molecular methods described in the above Examples.
  • HSCs While as few as l-io HSCs are able to colonize and repopulate a lethally-irradiated recipient mouse over time, it is advantageous to optimize the rate at which repopulation occurs in a human HSC transplant patient; therefore, 10 to 100, or even 100 to 1000 HCSs produced by the methods of the present invention should be administered in order to be therapeutically effective.
  • EXAMPLE 7 Long-term hempatopoietic stem cell growth in AGM explants. Since the AGM region is a rapidly-growing embryonic area which changes in size, complexity and function from E10 to E13, it is of great importance to determine the viability and function of this microenvironment for the induction/growth/expansion of hematopoietic stem cells over long periods of time. Thus, we have cultured marked AGM explants for a period greater than 2-3 days and tested for the presence of hematopoietic stem cells by the long term adult repopulation assay.
  • EXAMPLE 8 Preparation of AGM cells for the support of HCS culture While intact AGM tissue, whether derived from the entire region or from the anterior or posterior regions, is of use according to the methods of the invention, it is also advantageous to dissociate the tissue into its component cells prior to culturing. In such experiments, reaggregation of dissociated cells, whether alone or mixed with exogenously-derived HSCs and/or pre-HSCs, into a solid or semi-solid mass has been observed to take place, and generation and/or expansion of HSCs has occurred in such cultures, as determined by the methods described above for the monitoring of HSC proliferation in intact- or anterior AGM cultures.
  • AGM tissue is digested with collagenase, as described above, and cells are seeded into tissue culture flasks or dishes in an appropriate medium, also as described above, and cultured.
  • Foci are individually harvested and cloned by standard methods; following establishment and expansion of a number of such cell lines, the candidate clones are mixed with HSCs and/or pre-HSCs, resulting chimerae are cultured simlilar to intact AGM tissue, and the HSCs generated by the cultures quantitated either by immunological staining or by repopulation of lethally-irradiated mice, all as described above. Clones that support HSC generation and/or expansion are then retained for further use.
  • HSCs produced according to the invention are useful for therapy, such as bone marrow transplants, gene therapy and for the production of blood related proteins either in in vivo or in vitro production systems.
  • a culture of HSCs or an enriched culture of HSCs is prepared according to the invention, for example, wherein the culture contains 0.1%-1.0% HSCs, is administered to a mammal in need thereof in a biocompatible manner (i.e., wherein the HSCs administered are able to repopulate the recipient blood system) , and in an amount which suffices to treat the disorder in the mammal which has reduced or compromised the mammal's blood system, as described below.
  • a culture of HSCs or an enriched culture of HSCs is prepared as described above via transfection of the HSCs with a gene of interest.
  • Stem cell transfection techniques are described above.
  • a therapeutic gene is one which is expressible in a mammalian, preferably a human, cell and encodes RNA or a polypeptide that is of therapeutic benefit to a mammal, preferably a human.
  • genes are well known in the art and include but are not limited to the ⁇ -glucocerebrosidase gene, the Bruton's thymidine kinase gene, genes encoding cytokines, such as TNF, interleukins 1-12, interferons ( ⁇ , ⁇ , 7 ) , Fc receptor, and T-cell receptor.
  • genes encoding inhibitors of HIV e.g., TAT or REV mutants that act as competitive inhibitors of the natural proteins.
  • the gene of interest may be carried in a vector, which vector may also include marker .genes, such as drug resistance genes, the ⁇ -galactosidase gene, the dihydrofolate reductase gene, and the chloramphenicol acetyl transferase gene.
  • Non-transfected and transfected HSCs are administered via ex vivo gene therapy (see Anderson et al., U.S. Patent No. 5,399,346).
  • the mode of administration is not critical to the invention, and may include for example, administration preferably in a biologically compatible solution or a pharmaceutically acceptable delivery vehicle, by ingestion, injection, inhalation or any number of other methods, i.e., via intravenous, intraperitoneal, and intradermal routes.
  • the dosages administered will vary from patient to patient; a "therapeutically effective dose" will be determined by the level of enhancement of function of the transferred genetic material balanced against any risk or deleterious side effects.
  • a "therapeutically effective dose” will be determined by the level of enhancement of function of the transferred genetic material balanced against any risk or deleterious side effects.
  • the therapeutic gene encodes a product of physiological importance, such as replacement of a defective gene or an additional potentially beneficial gene function
  • administration of transfected HSCs to a mammal in need thereof is expected to confer long term genetic modification of the cells and be effective in the treatment of disease.
  • the genetic modification and long term benefit may be determined by detecting the gene product in the treated mammal at various time points (i.e., several days or weeks or months or years) after administration, or by detecting a marker which indicates correction or amelioration of the disease. Monitoring levels of gene introduction, gene expression and/or the presence or levels of the encoded product will assist in selecting and adjusting the dosages administered.
  • Absolute numbers of HSCs used to repopulate an individual substantially lacking hematopoietic cells may, in theory, be as low as 1 to 10 in number; however, such a small number of cells would require a lengthy period of proliferation and differentiation before repopulation was effectively complete.
  • a thereapeutically useful number of HSCs should, at a minimum, be 100 cells for a human recipient.
  • a composition according to the invention will be administered in a single dose of preferably 100 to 1,000 cells, more preferably, 1,000 to 10,000 cells and most preferably, up to 10,000 to 100,000 cells. If desired, multiple doses may be administered, as needed.
  • HSCs provided according to the invention may be used to treat X-linked 0-globulinemia.
  • a selected vector containing the gene of interest will contain the minimal sequences described herein, i.e., an origin of replication for replication in a bacterial or yeast host cell, an operator sequence, and a site for insertion of a therapeutic gene.
  • the pUCl ⁇ tet plasmid may be used as a minimal plasmid, preferably with the tet gene deleted.
  • the therapeutic gene may be the Bruton's kinase gene (Vetrie et al., 1993, Nature, 361: 226-233), and is carried on the following DNA fragments, which are cloned together using procedures well-known in the art.
  • the Bruton's Tyrosine Kinase human gene is carried on a 2.1 kb fragment delineated by the Pvul site at position (+33) and the Hindlll site at position (+2126) .
  • the vector also may include sequences which confer position independent, tissue specific gene expression, as taught in PCT/GB88/00655.
  • the therapeutic gene may also encode a splice site and poly-A tail, which may include portions of the human ⁇ globin locus splice and poly A signals; i.e., a BamHI - Xbal 2.8 kb 3' splice/poly- A flanking sequence containing exon 2 - IVSII - exon 3 - polyA sequences.
  • Vector DNA may be prepared as described herein and used to treat X-linked ?-globulinemia by introducing vector- transfected HCSs for ex vivo therapy, and administering the transfected cells into a patient afflicted with X-linked /3-globulinemia.
  • HSCs prepared according to the invention also may be used for treatment of Gaucher's disease.
  • Gaucher's disease stems from one of two different genetic mutations.
  • Gaucher's type 1 is a CGG —> CAG mutation, which results in an Arg —> Gin substitution at position 119 of the ⁇ -glucocerebrosidase polypeptide (Graves, 1988, DNA. 7: 521).
  • Gaucher's type 2 is a CTG - -> CCG mutation, which results in a Leu —> Pro substitution at position 444 of the ⁇ -glucocerebrosidase polypeptide (Tsuji, 1987, New England J. Med. f 316: 570).
  • Another vector useful according to the invention for transfecting HSCs is one containing the minimal elements described herein (i.e., an origin of replication, an operator sequence, and a cloning site) and the lysozyme gene promoter and the ⁇ -glucocerebrosidase transgene, as described in Horowitz et al., 1989, Geno ics, 4: 87-96.
  • This plasmid is constructed as follows.
  • the human ⁇ -glucocerebrosidase gene is carried (as disclosed in Horowitz et al., 1989, supra) on a 9722 base pair fragment extending from a BamHI site in exon 1 to an EcoRV site 3* to polyadenylation site. This fragment contains 11 exons and all intervening sequences, with translational start in exon 2. Sequences conferring position-independent and tissue-specific gene expression may be included in the construct and are carried on an 11.8 kb Xhol - Sad fragment from plll.lyx construct as described in Bonifer et al., 1990, EMBO J.. 9: 2843.
  • DNA is prepared as described herein and is then used to treat Gaucher's disease by introducing the DNA into HSCs as described above and then administering the transfected HSCs into a patient afflicted with Gaucher's disease.
  • Expression of the wild type transgene in a patient afflicted with Gaucher's disease should result in correction of the diseased state.
  • HSCs are prepared according to the invention, whether untransfected or transfected with a gene of interest.
  • In vivo protein production systems for example, animals which carry a gene of interest, are well-known in the art.
  • HSCs are administered to an animal such as a mouse, pig, goat, or cow, in the same cell numerical range described above for disease treatment, and the protein of interest (i.e., produced by the HSCs) is obtained from the animal by removing blood from the animal and isolating the protein of interest using techniques known in the art for isolation of that protein of interest.
  • a culture of HSCs is provided as described herein, and the protein is isolated according to standard techniques.
  • Embryonic tissues were cultured as described in Figure 1 and tested for CFU-S,, generation. The number of CFU-S per tissue and CFU-S per 10 6 cells are shown. In two representative experiments, the total numbers of 32-33 and 34-35 somite pair embryos used for organ cultures were 4 and 3 respectively.
  • Temporal dynamics (at day 10 and 11 p.c.) of the in vitro CFU-S, progenitor production is shown in Figure 3 for cultured YS, AGM region and liver. In recipient mice transplanted with cultured body remnants we found some CFU-S production which likely represents contamination with the AGM region (as the AGM region is juxtaposed the somites and lateral walls of the embryo) .
  • Table 2 Table 2
  • the number of reconstituted, donor positive recipients and the total number of recipients transplanted with cultured embryonic tissues is shown. Tissues from day 10 p.c. embryos (35-38 somite pairs) were explanted to organ cultures as described in Figure 1. Only male tissues were transplanted into lethally irradiated female recipients. The number of reconstituted donor positive recipients was determined by TMT2/B specific PCR analysis of peripheral blood DNA at the post-transplantation times shown as described in the Materials and Methods. Semi-quantitative PCR showed the above number of recipients were reconstituted with greater than 10% donor cells. We also observed some reconstituted animals with about 1% donor contribution as follows: 3/27 with cultured AGM region, 1/16 with cultured YS and 1/4 with cultured body remnants.
  • Reconstitution data obtained after one month post transfer Positive recipients were identified by PCR amplification of the donor Lac-Z signal from genomic DNA obtained from blood. Level of reconstitution was determined as indicated in Table 2. Only recipients with signal >10% are considered positive.
  • the mean number of injected cells per recipient is shown and the range is indicated in parentheses.
  • tissue cell type number of donor cells reconstituted experiments per recipient recipients/ (x 1000) total recipients
  • CD34 + 8 50 (15-100) 5/18 c-kit+ 8 6.6 (3-10) 0/18
  • Mac-1+ 3 21 (15-30) 4/8 c-kit+ 4 5 (4-5) 0/10
  • Cells were stained with FITC-conjugated anti-c-kit and PE- conjugated anti-CD34 mAbs or with FITC-conjugated anti-c- kit and PE-conjugated anti-Mac-1 mAbs and sorted according to the gates indicated in fig 3. Each sorted subset was i.v. injected into irradiated recipients mice.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne un système de mise en culture in vitro permettant la prolifération de cellules souches hématopoïétiques (HSC) de mammifères.
PCT/GB1997/002549 1996-09-19 1997-09-19 Systeme de mise en culture de cellules souches hematopoietiques WO1998012304A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU43111/97A AU4311197A (en) 1996-09-19 1997-09-19 Culture system for hematopoietic stem cells

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US2574796P 1996-09-19 1996-09-19
GBGB9619597.9A GB9619597D0 (en) 1996-09-19 1996-09-19 Culture system
GB9619597.9 1996-09-19
US60/025,747 1996-09-19
US2773596P 1996-10-03 1996-10-03
US60/027,735 1996-10-03
US93360097A 1997-09-18 1997-09-18
US08/933,600 1997-09-18

Publications (1)

Publication Number Publication Date
WO1998012304A1 true WO1998012304A1 (fr) 1998-03-26

Family

ID=27451524

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/002549 WO1998012304A1 (fr) 1996-09-19 1997-09-19 Systeme de mise en culture de cellules souches hematopoietiques

Country Status (2)

Country Link
AU (1) AU4311197A (fr)
WO (1) WO1998012304A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1192243A1 (fr) * 1999-06-23 2002-04-03 Oregon Health and Science University Procede destine a promouvoir l'hematopoiese
US6821513B1 (en) 1999-06-23 2004-11-23 Oregon Health & Science University Method for enhancing hematopoiesis
US6933150B1 (en) 1998-05-28 2005-08-23 St. Jude Children's Research Hospital Relationship of ABC transport proteins with hematopoietic stem cells and methods of use thereof
KR100789501B1 (ko) * 1999-03-12 2007-12-28 브이이씨 테크놀러지, 인코포레이티드 복합 물품 성형 방법 및 장치
US7622557B2 (en) 1998-05-28 2009-11-24 St. Jude Children's Research Hospital Antibodies having binding specificity for the extracellular domain of a breast cancer resistance protein (BCRP)
WO2018161121A1 (fr) * 2017-03-08 2018-09-13 Murdoch Childrens Research Institute Procédés de production de progéniteurs de lymphocytes

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DZIERZAK E ET AL: "Induction and expansion of hematopoietic stem cells in the AGM region of the developing mouse embryo.", THIRTY-EIGHTH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, ORLANDO, FLORIDA, USA, DECEMBER 6-10, 1996. BLOOD 88 (10 SUPPL. 1 PART 1-2). 1996. 444A, XP002052538 *
DZIERZAK E ET AL: "The AGM region: Initiation and characterization of the first definitive hematopoietic stem cells in the mouse embryo.", 26TH ANNUAL MEETING OF THE INTERNATIONAL SOCIETY FOR EXPERIMENTAL HEMATOLOGY, CANNES, FRANCE, AUGUST 24-28, 1997. EXPERIMENTAL HEMATOLOGY (CHARLOTTESVILLE) 25 (8). 1997. 876, XP002052540 *
DZIERZAK E. ET AL.: "Mouse embryonic hematopoiesis", TRENDS IN GENETICS, vol. 11, no. 9, September 1995 (1995-09-01), pages 359 - 366, XP002052536 *
MEDVINSKY A ET AL: "Definitive hematopoiesis is autonomously initiated by the AGM region.", CELL 86 (6). 1996. 897-906, XP002052539 *
MEDVINSKY A L ET AL: "Development of day-8 colony-forming unit-spleen hematopoietic progenitors during early murine embryogenesis: Spatial and temporal mapping.", BLOOD 87 (2). 1996. 557-566, XP002052535 *
MUELLER, ALBRECHT M. ET AL: "Development of hematopoietic stem cell activity in the mouse embryo", IMMUNITY (1994), 1(4), 291-301, XP002052537 *
SANCHEZ, MARIA-JOSE ET AL: "Characterization of the first definitive hematopoietic stem cells in the AGM and liver of the mouse embryo", IMMUNITY (1996), 5(6), 513-525, XP002052541 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6933150B1 (en) 1998-05-28 2005-08-23 St. Jude Children's Research Hospital Relationship of ABC transport proteins with hematopoietic stem cells and methods of use thereof
US7622557B2 (en) 1998-05-28 2009-11-24 St. Jude Children's Research Hospital Antibodies having binding specificity for the extracellular domain of a breast cancer resistance protein (BCRP)
US7906331B2 (en) 1998-05-28 2011-03-15 St. Jude Children's Research Hospital Methods for identifying stem cells expressing breast cancer resistance protein (BCRP)
KR100789501B1 (ko) * 1999-03-12 2007-12-28 브이이씨 테크놀러지, 인코포레이티드 복합 물품 성형 방법 및 장치
EP1192243A1 (fr) * 1999-06-23 2002-04-03 Oregon Health and Science University Procede destine a promouvoir l'hematopoiese
EP1192243A4 (fr) * 1999-06-23 2003-05-28 Univ Oregon Health & Science Procede destine a promouvoir l'hematopoiese
US6821513B1 (en) 1999-06-23 2004-11-23 Oregon Health & Science University Method for enhancing hematopoiesis
WO2018161121A1 (fr) * 2017-03-08 2018-09-13 Murdoch Childrens Research Institute Procédés de production de progéniteurs de lymphocytes
US20200399390A1 (en) * 2017-03-08 2020-12-24 Murdoch Childrens Research Institute Methods for producing lymphocyte progenitors
EP3592844A4 (fr) * 2017-03-08 2021-01-13 Murdoch Childrens Research Institute Procédés de production de progéniteurs de lymphocytes

Also Published As

Publication number Publication date
AU4311197A (en) 1998-04-14

Similar Documents

Publication Publication Date Title
Sánchez et al. Characterization of the first definitive hematopoietic stem cells in the AGM and liver of the mouse embryo
US5744347A (en) Yolk sac stem cells and their uses
US7919316B2 (en) Hematopoietic stem cell identification and isolation
US6093531A (en) Generation of hematopoietic cells from multipotent neural stem cells
US20050221482A1 (en) Methods and compositions for obtaining hematopoietic stem cells derived from embryonic stem cells and uses thereof
JPH07508658A (ja) ヒト造血幹細胞の生着，増殖及び分化のための動物モデル
US6821513B1 (en) Method for enhancing hematopoiesis
US20080171384A1 (en) Method of obtaining a population of human haemopoietic stem cells
Broxmeyer Cord blood as an alternative source for stem and progenitor cell transplantation
Chou et al. In utero transplantation of human bone marrow‐derived multipotent mesenchymal stem cells in mice
US20030100107A1 (en) Compositions and methods for generating differentiated human cells
WO1998012304A1 (fr) Systeme de mise en culture de cellules souches hematopoietiques
WO1999003980A1 (fr) Cellules de stroma derivees d'agm
Farace et al. Evaluation of hematopoietic potential generated by transplantation of muscle-derived stem cells in mice
AU661709B2 (en) Yolk sac stem cells
JP2025066198A (ja) 造血幹細胞移植における移植前処理を受けた患者を処置する方法および当該方法に用いるための組成物
Herbst et al. Adoptive transfer of the hematopoietic system of trisomic mice with limited life span: stem cells from six different trisomies are capable of survival
Stewart Stem Cells and Stem Cell therapies: the Future for Regenerative Medicine?
CA2375527A1 (fr) Procede destine a promouvoir l'hematopoiese
Götherström Characterisation of human fetal mesenchymal stem cells
Dejbakhsh-Jones et al. Early Defect Prethymic in Bone Marrow T Cell
Campos Role Of The Proto-Oncogene Ret During Haematopoietic Differenciation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998514406

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载